to the State Medicaid Agency and the Protection and Advocacy Organization. They are also required to provide residents the restraint and seclusion policy in writing, and to document in the residents' records all activities involving the use of restraint and seclusion. Form Number: CMS-R-306 (OMB Control Number 0938-0833); Frequency: Occasionally; Affected Public: Private sector (Business or other for-profits); Number of Respondents: 390; Total Annual Responses: 1,466,823; Total Annual Hours: 449,609. (For policy questions regarding this collection contact Kirsten Jensen at 410-786-8146).

Dated: June 14, 2018.

William N. Parham, III,

Director, Paperwork Reduction Staff, Office of Strategic Operations and Regulatory Affairs.

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Administration for Children and Families

Proposed Information Collection Activity; Comment Request

Proposed Projects: Emergency Repatriation (After Analysis Questionnaire).

ANNUAL BURDEN ESTIMATES

Title: Evaluation of Services provided to Repatriates.

OMB No.:

Description: The Department of Health and Human Services, Administration for Children and Families, Office of Refugee Resettlement (ORR) is conducting an after event analysis of the activation of the Emergency Repatriation Plan and overall response during recent emergency repatriation. In an effort to strengthen our operations, learn from our experience, and ensure quality services in future similar efforts. (Evaluation of services provided).

Respondents: Repatriates (International Social Services ISS–USA).

Instrument	Number of respondents	Number of responses per respondent	Average burden hours per response	Total burden hours
(Repatriates Questionnaire) Assessment	100–5000 100–500	1 1	1 1	1

Estimated Total Annual Burden Hours: 2 Hours.

In compliance with the requirements of the Paperwork Reduction Act of 1995 (Pub. L. 104-13, 44 U.S.C. Chap 35), the Administration for Children and Families is soliciting public comment on the specific aspects of the information collection described above. Copies of the proposed collection of information can be obtained and comments may be forwarded by writing to the Administration for Children and Families, Office of Planning, Research and Evaluation, 330 C Street SW, Washington, DC 20201. Attn: ACF Reports Clearance Officer. Email address: infocollection@acf.hhs.gov. All requests should be identified by the title of the information collection.

The Department specifically requests comments on: (a) Whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information shall have practical utility; (b) the accuracy of the agency's estimate of the burden of the proposed collection of information; (c) the quality, utility, and clarity of the information to be collected; and (d) ways to minimize the burden of the collection of information on

respondents, including through the use of automated collection techniques or other forms of information technology. Consideration will be given to comments and suggestions submitted within 60 days of this publication.

Robert A. Sargis,

Reports Clearance Officer.
[FR Doc. 2018–13060 Filed 6–18–18; 8:45 am]
BILLING CODE 4184–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket Nos. FDA-2013-N-0545; FDA-2013-N-0878; FDA-2014-N-0998; FDA-2014-N-1076; FDA-2017-N-6162; FDA-2011-N-0510; FDA-2014-N-1414; FDA-2008-D-0610; FDA-2010-D-0073; FDA-2013-N-0080; FDA-2017-N-6397; FDA-2014-D-0313; FDA-2014-N-1030; and FDA-2014-D-1837]

Agency Information Collection Activities; Announcement of Office of Management and Budget Approvals

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is publishing a list of information collections that have been approved by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995.

FOR FURTHER INFORMATION CONTACT: Ila S. Mizrachi, Office of Operations, Food and Drug Administration, Three White Flint North, 10A–12M, 11601 Landsdown St., North Bethesda, MD 20852, 301–796–7726, PRAStaff@fda.hhs.gov.

SUPPLEMENTARY INFORMATION: The following is a list of FDA information collections recently approved by OMB under section 3507 of the Paperwork Reduction Act of 1995 (44 U.S.C. 3507). The OMB control number and expiration date of OMB approval for each information collection are shown in table 1. Copies of the supporting statements for the information collections are available on the internet at https://www.reginfo.gov/public/do/ PRAMain. An Agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number.

TABLE 1—LIST OF INFORMATION COLLECTIONS APPROVED BY OMB

Title of collection		Date approval expires
Infant Formula Requirements	0910-0256	5/31/2021
Premarket Notification for a New Dietary Ingredient	0910-0330	5/31/2021
Regulations for In Vivo Radiopharmaceuticals Used for Diagnosis and Monitoring	0910-0409	5/31/2021
Guidance for Industry: Formal Dispute Resolution; Scientific and Technical Issues Related to Pharmaceutical		
Current Good Manufacturing Practice	0910-0563	5/31/2021
Requests for Inspection by an Accredited Person Under the Inspection for Accredited Persons Program	0910-0569	5/31/2021
Substances Prohibited from Use in Animal Food or Feed	0910-0627	5/31/2021
Class II Special Controls Guidance Document: Labeling for Natural Rubber Latex Condoms Classified Under		
21 CFR 884.5300	0910–0633	5/31/2021
Guidance for Industry: Postmarketing Adverse Event Reporting for Medical Products and Dietary Supplements		
During an Influenza Pandemic	0910–0701	5/31/2021
Guidance on Consultation Procedures: Foods Derived From New Plant Varieties	0910–0704	5/31/2021
Human Subject Protection; Acceptance of Data From Clinical Investigations for Medical Devices	0910–0741	5/31/2021
Food Labeling; Calorie Labeling of Articles of Food in Vending Machines and Nutrition Labeling of Standard		
Menu Items in Restaurants and Similar Retail Food Establishments	0910–0782	5/31/2021
Guidance for Industry, Researchers, Patient Groups, and Food and Drug Administration Staff on Meetings with		
the Office of Orphan Products Development	0910–0787	5/31/2021
Food Allergen Labeling and Reporting	0910-0792	5/31/2021
Transfer of a Premarket Notification Clearance	0910–0852	5/31/2021

Dated: June 13, 2018.

Leslie Kux.

Associate Commissioner for Policy.
[FR Doc. 2018–13098 Filed 6–18–18; 8:45 am]
BILLING CODE 4164–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Health Resources and Services Administration

Ryan White HIV/AIDS Program Parts A and B Integrated HIV Planning Implementation Cooperative Agreement to John Snow, Inc. (JSI), U69HA30144

AGENCY: Health Resources and Services Administration (HRSA), Department of Health and Human Services.

ACTION: Notice of non-competitive FY 2018 supplemental award.

SUMMARY: This noncompetitive supplement award to JSI will support and strengthen current Ryan White HIV/AIDS Program (RWHAP) Part A and Part B priority setting and resource allocation processes to ensure people living with HIV are linked to care, remain engaged in care, and achieve viral suppression.

FOR FURTHER INFORMATION CONTACT: Dr. Rene Sterling, Acting Director, Division of State HIV/AIDS Programs, HIV/AIDS Bureau, HRSA; 5600 Fishers Lane, Room 09W50, Rockville, MD 20857; Phone: (301) 443–9017, Email: rsterling@hrsa.gov.

SUPPLEMENTARY INFORMATION:

Intended Recipient of the Award: JSI (U69HA30144).

Amount of Non-Competitive Award: \$300,000 in FY 2018.

Period of Funding: July 1, 2018, through June 30, 2019.

CFDA Number: No. 93.145.

Authority: Sections 2606 and 2654(b) of the Public Health Service Act, as amended by the Ryan White HIV/AIDS Treatment Extension Act of 2009 (Pub. L. 111–87).

Justification: In 2016, JSI was awarded a 3-year cooperative agreement under HRŠA-16-082 RWHAP Integrated HIV Planning Implementation (CFDA) 93.145), authorized by Sections 2606 and 2654(b) of the Public Health Service Act, as amended by the Ryan White HIV/AIDS Treatment Extension Act of 2009 (Pub. L. 111-87). The cooperative agreement was established to provide technical assistance to RWHAP Parts A and B recipients and their planning bodies regarding: (1) The integration of HIV planning across prevention, care, and treatment service delivery systems; and (2) the development, implementation, monitoring, and evaluation of Integrated HIV Prevention and Care Plans. RWHAP Parts A and B recipients and planning bodies use Integrated Plans to better inform and coordinate HIV prevention and care program planning, resource allocation, and continuous quality improvement efforts to meet the HIV service delivery needs within their jurisdictions.

The proposed supplemental funding will provide RWHAP Parts A and B recipients with additional technical assistance (TA) specifically focused on resource allocation planning and implementation. These additional TA activities will build upon data elements identified in the Integrated Plan and

provide jurisdictions with strategies, tools, and resources to effectively allocate annual available resources to prioritize HIV unmet needs. The TA activities will be directed at addressing more efficient and proactive methods in the Priority Setting and Resource Allocation (PSRA) process to increase the ability of health care providers and systems to ensure people living with HIV are linked to care, remain engaged in care, and achieve HIV viral suppression.

Dated: June 12, 2018.

George Sigounas,

Administrator.

[FR Doc. 2018-13121 Filed 6-18-18; 8:45 am]

BILLING CODE 4165-15-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Allergy and Infectious Diseases; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which